DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

AMYRIS INC COM (NASDAQ: AMRS)

2.27 -0.03 (-1.30%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AMRS $2.27 -1.30%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.27
Previous Close $2.30
Daily Range $2.25 - $2.39
52-Week Range $2.03 - $6.11
Market Cap $179.5M
P/E Ratio -0.82
Dividend (Yield) $0.00 (0.0%)
Volume 292,760
Average Daily Volume 159,235
Current FY EPS -$1.23

Sector

Healthcare

Industry

Drugs

AMYRIS INC COM (AMRS) Description

Amyris Inc. is building a renewable products company by applying its industrial synthetic biology technology platform to provide alternatives to select petroleum-sourced products used in specialty chemical and transportation fuel markets worldwide. Website: http://www.amyris.com/

News & Commentary Rss Feed

Falling Oil Prices Could Kill Environmentally-Friendly Jet Fuels

Falling oil prices will boost profits in the airline industry, but could hamper plans to switch to more environmentally-friendly options.

This Gene Editing Technology Is About to Change Healthcare and GMOs Forever

A former AbbVie executive recently said, "We talk about paradigm shifts a lot in this industry, but this really is." What makes gene-editing platforms so promising and inevitable -- and what stocks are at risk of becoming obsolete?

Energy Investing: 4 Reasons We're Excited for 2015

The Motley Fool asked the analysts knee-deep in the energy sector what they're excited about for 2015.

Why Amyris (AMRS) Could Be Positioned for a Slump - Tale of the Tape

Can Biotech Save Natural Gas Producers Billions in Flaring Costs?

Last year the United States ignited nearly $1 billion worth of natural gas because it didn't have the infrastructure required to capture and store it. While producers aren't incentivized to capture and flood the market with gas that is currently flared, biotech could provide a reliable and profitable solution.

Should You Buy Solazyme After Its Big Drop?

Solazyme stock went cliff-diving last week. Is it time to buy?

2 Airlines Are Already Using Biofuels, So Why Aren't We All Flying Green?

Biofuels aren't just for your cars anymore. With major airlines taking a serious look, will you be on a bio-flight soon?

Solazyme Pivots Commercialization Strategy, But Does Amyris Do It Better?

Solazyme realized that it needs to sell high value products to survive, but Amyris realized that over 12 months ago. What can investors learn from execution at Amyris, and how does it translate to the new strategy at Solazyme?

Amyris' (AMRS) CEO John Melo on Q3 2014 Results - Earnings Call Transcript

Amyris (AMRS) Q3 2014 Results - Earnings Call Webcast

See More AMRS News...

AMRS's Top Competitors

AMRS $2.27 (-1.30%)
Current stock: AMRS
FCEL $1.59 (-1.85%)
Current stock: FCEL
CDXS $2.50 (-1.19%)
Current stock: CDXS
RTK $1.20 (-1.64%)
Current stock: RTK